Leith Wheeler Investment Counsel Ltd. lessened its position in shares of Henry Schein, Inc. (NASDAQ:HSIC – Free Report) by 2.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 355,314 shares of the company’s stock after selling 8,079 shares during the period. Henry Schein makes up about 2.2% of Leith Wheeler Investment Counsel Ltd.’s portfolio, making the stock its 12th largest holding. Leith Wheeler Investment Counsel Ltd.’s holdings in Henry Schein were worth $26,187,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. Dimensional Fund Advisors LP increased its stake in Henry Schein by 2.0% in the first quarter. Dimensional Fund Advisors LP now owns 2,873,004 shares of the company’s stock valued at $211,734,000 after acquiring an additional 56,687 shares during the last quarter. Parallel Advisors LLC lifted its stake in Henry Schein by 12.7% during the first quarter. Parallel Advisors LLC now owns 1,314 shares of the company’s stock worth $97,000 after purchasing an additional 148 shares during the last quarter. SEB Asset Management AB acquired a new stake in shares of Henry Schein in the 1st quarter valued at $2,276,000. Bessemer Group Inc. boosted its holdings in shares of Henry Schein by 9.8% in the 1st quarter. Bessemer Group Inc. now owns 6,990 shares of the company’s stock valued at $515,000 after purchasing an additional 626 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Henry Schein by 0.6% in the 1st quarter. Bank of New York Mellon Corp now owns 545,599 shares of the company’s stock valued at $40,211,000 after purchasing an additional 3,380 shares during the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.
Henry Schein Trading Down 1.8%
Shares of HSIC stock opened at $86.20 on Tuesday. The firm has a market capitalization of $9.82 billion, a P/E ratio of 26.04, a P/E/G ratio of 1.69 and a beta of 0.81. Henry Schein, Inc. has a twelve month low of $61.94 and a twelve month high of $89.34. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59. The stock’s fifty day simple moving average is $79.85 and its 200 day simple moving average is $77.79.
Insider Transactions at Henry Schein
In other Henry Schein news, Director William K. Daniel acquired 10,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average price of $69.19 per share, for a total transaction of $691,900.00. Following the acquisition, the director directly owned 20,000 shares in the company, valued at $1,383,800. This represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.89% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Several brokerages recently weighed in on HSIC. BMO Capital Markets initiated coverage on Henry Schein in a research report on Wednesday, July 8th. They set a “market perform” rating and a $85.00 price objective for the company. Wall Street Zen downgraded Henry Schein from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Citigroup initiated coverage on shares of Henry Schein in a report on Wednesday, April 15th. They issued a “buy” rating and a $100.00 target price for the company. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Henry Schein in a report on Monday, May 4th. Finally, Mizuho decreased their price target on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $87.64.
View Our Latest Research Report on Henry Schein
Henry Schein Profile
Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.
In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.
Featured Articles
- Five stocks we like better than Henry Schein
- The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
- Is Domino’s Stock Serving Up a Buying Opportunity?
- A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free
- Why Gold Miners Could Be the Market’s Biggest Comeback Story
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC – Free Report).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
